GRL0617

GRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an EC50 of 14.5 μM. GRL0617 can be used for the research of severe acute respiratory syndrome[1].

Product Specifications

CAS Number

[1093070-16-6]

Product Name Alternative

8-Nitrotryptanthrin

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Deubiquitinase; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/grl-0617.html

Concentration

10mM

Purity

99.62

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](C1=C2C=CC=CC2=CC=C1)C)C3=CC(N)=CC=C3C

Molecular Formula

C20H20N2O

Molecular Weight

304.39

Precautions

H302, H315, H319, H335

References & Citations

[1]Ratia K, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A. 2008 Oct 21;105 (42) :16119-24.